WAYNE, Pa., June 23, 2015 /PRNewswire/ -- Ryan & Maniskas, LLP that a class action lawsuit has been filed in United States District Court for the Central District of California on behalf of all persons or entities that purchased the common stock of Puma Biotechnology, Inc. ("Puma" or the "Company") (NYSE: PBYI) between July 23, 2014 and May 13, 2015, inclusive (the "Class Period").

http://photos.prnewswire.com/prnvar/20121112/MM11729LOGO

Puma shareholders may, no later than August 3, 2015, move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Puma and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/pbyi.

Puma is a biopharmaceutical company that focuses on in-licensing cancer drug candidates that have already undergone or completed clinical testing. The complaint alleges that Puma made false and/or misleading statements and/or failed to disclose in violation of the securities laws that: (1) the Company's NDA filing would be for a positive early stage breast cancer indication, instead of the previously announced metastatic breast cancer; (2) Puma would need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which Puma did not have; (3) the additional studies required would push the timeline for filing the NDA into the first quarter of 2016; (4) the Company overstated results from its Phase III ExteNET Trial; and (5) as a result of the foregoing, Puma lacked a reasonable basis for their positive statements concerning the Company's outlook, as well as the ongoing ExteNET trial. When the truth was revealed, the stock dropped causing damage to investors.

If you are a member of the class, you may, no later than August 3, 2015, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information regarding this, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/pbyi. For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
484-588-5516
877-316-3218
www.rmclasslaw.com/cases/pbyi
rmaniskas@rmclasslaw.com

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-class-action-lawsuit-against-puma-biotechnology-inc-300103522.html

SOURCE Ryan & Maniskas, LLP